Intellia Therapeutics (NASDAQ:NTLA) Trading 7.3% Higher – Should You Buy?

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) traded up 7.3% during trading on Friday . The stock traded as high as $14.04 and last traded at $14.04. 3,674,520 shares changed hands during mid-day trading, a decline of 31% from the average session volume of 5,364,061 shares. The stock had previously closed at $13.09.

More Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its earnings estimates across multiple periods, including FY2026, signaling a modestly improved outlook for Intellia Therapeutics.
• Positive Sentiment: The firm kept a Buy rating and $25 price target, reinforcing bullish sentiment after recent first-quarter results. Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $25.00 by Analysts at HC Wainwright
• Neutral Sentiment: Other recent coverage, including Hold ratings from Wells Fargo and Wedbush, suggests overall analyst opinion remains mixed despite the upbeat HC Wainwright revisions. Wells Fargo Remains a Hold on Intellia Therapeutics (NTLA)
• Negative Sentiment: Even after the estimate increases, Intellia is still expected to report losses for 2026 and 2027, reflecting ongoing profitability concerns.

Analyst Upgrades and Downgrades

NTLA has been the topic of a number of recent research reports. Citigroup restated an “outperform” rating on shares of Intellia Therapeutics in a research note on Tuesday, April 28th. Wedbush reiterated a “neutral” rating and set a $12.00 target price on shares of Intellia Therapeutics in a research note on Tuesday. Truist Financial raised Intellia Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Bank of America reaffirmed a “neutral” rating on shares of Intellia Therapeutics in a research note on Monday, March 2nd. Finally, Chardan Capital increased their price objective on Intellia Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, April 27th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $20.25.

Intellia Therapeutics Trading Up 3.7%

The company has a market cap of $1.90 billion, a price-to-earnings ratio of -3.85 and a beta of 1.93. The company’s 50 day moving average price is $13.64 and its 200 day moving average price is $11.98.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.11. The business had revenue of $15.05 million for the quarter, compared to analyst estimates of $13.81 million. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. During the same period in the previous year, the business posted ($1.10) earnings per share. Sell-side analysts predict that Intellia Therapeutics, Inc. will post -3.37 earnings per share for the current year.

Institutional Trading of Intellia Therapeutics

Several hedge funds have recently modified their holdings of the business. Comerica Bank grew its holdings in Intellia Therapeutics by 45.8% during the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after acquiring an additional 901 shares during the period. Headlands Technologies LLC acquired a new stake in Intellia Therapeutics in the second quarter valued at $26,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Intellia Therapeutics during the 3rd quarter worth $30,000. Advisory Services Network LLC purchased a new stake in shares of Intellia Therapeutics during the 3rd quarter worth $33,000. Finally, Spire Wealth Management acquired a new position in shares of Intellia Therapeutics during the 4th quarter worth $37,000. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.